<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02237612</url>
  </required_header>
  <id_info>
    <org_study_id>4P-08-4</org_study_id>
    <secondary_id>NCI-2014-01848</secondary_id>
    <secondary_id>HS-08-00413-CR004</secondary_id>
    <secondary_id>HS-08-00413</secondary_id>
    <secondary_id>4P-08-4</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT02237612</nct_id>
  </id_info>
  <brief_title>Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer</brief_title>
  <official_title>Diffusion-Weighted MRI for Staging in Localized Prostate Cancer: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies how well diffusion-weighted magnetic resonance imaging&#xD;
      (MRI) works in staging patients with prostate cancer that has not spread to nearby lymph&#xD;
      nodes or other parts of the body. New imaging techniques, such as diffusion-weighted MRI, may&#xD;
      be a less invasive way of predicting the stage and grade of prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the sensitivity and specificity of diffusion-weighted MRI for pathologic T3&#xD;
      stage prostate cancer using a 3 Tesla (3T) magnet with a surface coil.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo diffusion-weighted MRI of the pelvis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients found to have extracapsular extension and seminal vesicle involvement using Diffusion-Weighted MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Patients will be imaged using diffusion-weighted MR. Findings will be correlated with histopathologic findings at biopsy and/or prostatectomy.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Stage IIA Prostate Cancer</condition>
  <condition>Stage IIB Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (diffusion-weighted MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo diffusion-weighted MRI of the pelvis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diffusion-weighted magnetic resonance imaging</intervention_name>
    <description>Undergo diffusion-weighted MRI</description>
    <arm_group_label>Diagnostic (diffusion-weighted MRI)</arm_group_label>
    <other_name>diffusion-weighted MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (diffusion-weighted MRI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-documented adenocarcinoma of the prostate which is intermediate or high risk,&#xD;
             defined as possessing one or more of the following features:&#xD;
&#xD;
               -  Gleason &gt;= 7&#xD;
&#xD;
               -  &gt; 50% biopsy cores +&#xD;
&#xD;
               -  Prostate-specific antigen (PSA) &gt;= 10&#xD;
&#xD;
          -  Interested in undergoing a radical prostatectomy as definitive management for prostate&#xD;
             cancer&#xD;
&#xD;
          -  No clinical or radiographic evidence for distant metastatic disease&#xD;
&#xD;
               -  In subjects with PSA &lt; 20 no radiographic staging is required in the absence of&#xD;
                  clinical symptoms for distant metastatic disease; for those with PSA &gt; 20, a bone&#xD;
                  scan must document lack of concern for bone involvement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ineligible for surgery due to cardiac, pulmonary, or other major comorbidity factor&#xD;
&#xD;
          -  History of claustrophobia&#xD;
&#xD;
          -  Pacemaker or other implanted metal objects which would make subject ineligible for&#xD;
             MRI, per standard criteria&#xD;
&#xD;
          -  Unable to give written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Dorff</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 4, 2014</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2014</study_first_posted>
  <last_update_submitted>September 9, 2014</last_update_submitted>
  <last_update_submitted_qc>September 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

